As COVID-19 continues to spread across the United States, clinical trial sites and R&D labs are short-staffed and many are closed. Australia, though, has controlled the coronavirus outbreak – bioanalytical labs, CROs and sites are open for business and, as recognized as an essential service by the Australian Government, have been working throughout the pandemic. In this webinar, we’ll discuss the many advantages of moving your early phase trials to Australia, from models of speed, efficiency, and cost advantages, to the advanced medical facilities available for development. We will hear how Australia offers rapid solutions for new or delayed trials, as well as savings of up to 50% on clinical trial costs.
Dr Kurt Sales has over 20 years of experience in a career spanning research and development, research management and business development in the UK and South Africa. At Agilex Biolabs, Kurt is responsible for management and oversight of the Agilex Biolabs Immunoassay division.
Kurt has extensive expertise in pre-clinical and clinical assay development, cellular and molecular biology, molecular signaling, flow cytometry, cell-based models and biomarkers, notably in the areas of inflammation and immunology. He also has extensive experience ensuring strict GLP compliance for bioanalytical assays and preclinical safety testing through PK/PD/Biomarker assays.
Widely published with 45 peer-reviewed scientific papers in high impact journals, a book chapter and presentations at over 30 conferences, Kurt also received the prestigious Society for Reproduction and Fertility New Investigator Award.
Kurt has a Ph.D. in Medical Biochemistry, a Masters in Biochemistry, and Bachelors of Science in Medicine with Honours in Pharmacology and a Bachelor of Science in Biochemistry and Physiology. He has a Diploma in Business Organisation and Management and a Post Graduate Certificate in Management.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.